SPRY

ARS Pharmaceuticals, Inc. Common Stock

10.21

USD

SPRY Earnings Reports

Positive Surprise Ratio

SPRY beat 10 of 20 last estimates.

50%

Next Report

Date of Next Report

Mar 18, 2026

Estimate for Q4 25 (Revenue/ EPS)

$26.42M

-$0.44

Implied change from Q3 25 (Revenue/ EPS)

-18.71%

-15.38%

Implied change from Q4 24 (Revenue/ EPS)

-69.48%

-189.80%

ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, SPRY reported earnings of -0.52 USD per share (EPS) for Q3 25, missing the estimate of -0.48 USD, resulting in a -8.02% surprise. Revenue reached 32.50 million, compared to an expected 29.53 million, with a 10.06% difference. The market reacted with a +8.36% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 26.42 million USD, implying an decrease of -15.38% EPS, and decrease of -18.71% in Revenue from the last quarter.

FAQ

What were ARS Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.52, missing estimates by -8.02%, and revenue of $32.50M, 10.06% above expectations.

How did the market react to ARS Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 8.36%, changed from $8.20 before the earnings release to $8.88 the day after.

When is ARS Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 18, 2026.

What are the forecasts for ARS Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 8 analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.44 and revenue of $26.42M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.